p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
Eduardo Cepeda Cañedo, … , Michael Witcher, Josie Ursini-Siegel
Eduardo Cepeda Cañedo, … , Michael Witcher, Josie Ursini-Siegel
Published January 20, 2021
Citation Information: JCI Insight. 2021;6(4):e138382. https://doi.org/10.1172/jci.insight.138382.
View: Text | PDF
Research Article Cell biology Oncology

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors

Abstract

Triple-negative breast cancers (TNBCs) lack effective targeted therapies, and cytotoxic chemotherapies remain the standard of care for this subtype. Owing to their increased genomic instability, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are being tested against TNBCs. In particular, clinical trials are now interrogating the efficacy of PARPi combined with chemotherapies. Intriguingly, while response rates are low, cohort of patients do respond to PARPi in combination with chemotherapies. Moreover, recent studies suggest that an increase in levels of ROS may sensitize cells to PARPi. This represents a therapeutic opportunity, as several chemotherapies, including doxorubicin, function in part by producing ROS. We previously demonstrated that the p66ShcA adaptor protein is variably expressed in TNBCs. We now show that, in response to therapy-induced stress, p66ShcA stimulated ROS production, which, in turn, potentiated the synergy of PARPi in combination with doxorubicin in TNBCs. This p66ShcA-induced sensitivity relied on the accumulation of oxidative damage in TNBCs, rather than genomic instability, to potentiate cell death. These findings suggest that increasing the expression of p66ShcA protein levels in TNBCs represents a rational approach to bolster the synergy between PARPi and doxorubicin.

Authors

Eduardo Cepeda Cañedo, Stephanie Totten, Ryuhjin Ahn, Paul Savage, Deanna MacNeil, Jesse Hudson, Chantal Autexier, Genevieve Deblois, Morag Park, Michael Witcher, Josie Ursini-Siegel

×

Figure 4

p66ShcA-induced oxidative stress sensitizes TNBCs to doxorubicin/PARPi.

Options: View larger image (or click on image) Download as PowerPoint
p66ShcA-induced oxidative stress sensitizes TNBCs to doxorubicin/PARPi. ...
(A) Hs578T cells were cultured in the absence (DMSO) or presence of doxorubicin (10 nM) or PARPi (300 nM) alone or in combination for 48 hours. FLAG immunoprecipitates were blotted with pS36-p66ShcA or ShcA antibodies. Data are shown as average ratio of pS36-p66ShcA/p66ShcA ± SEM (n = 3 independent experiments). (B) Schematic diagram depicting p66ShcA-WT, p66-QQW, or p66-S36A mutants. (C) Immunoblot showing relative p66ShcA expression levels. (D) VC-, p66-WT–, p66-QQW–, or p66-S36A–expressing cells were treated with doxorubicin (1 nM) and PARPi (300 nM), alone or in combination. The number of viable cells was determined by trypan blue exclusion. The graphs show the average number of cells ± SEM (n = 3–6 independent experiments). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 1-way ANOVA/Tukey’s multiple comparisons test (A) and 2-way ANOVA/Tukey’s multiple comparisons test (D).